Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03).
Fiche publication
Date publication
février 2023
Journal
Clinical hematology international
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CAILLOT Denis
Tous les auteurs :
van de Wyngaert Z, Malard F, Hulin C, Caillot D, Mariette C, Facon T, Touzeau C, Perrot A, Moreau P, Hebraud B, Kanouni T, Heshmati F, Lebon D, Mohty M, Chabannon C
Lien Pubmed
Résumé
Despite the implementation of new therapeutic agents, management of relapsed multiple myeloma (MM) remains a challenge. Salvage autologous hematopoietic cell transplant (AHCT) remains a valid therapeutic option for eligible patients who achieve prolonged response after a first AHCT. However, a second graft is not always available, and these patients may need a second mobilization.
Mots clés
Plerixafor, Relapsed multiple myeloma, Salvage autologous transplant
Référence
Clin Hematol Int. 2023 02 12;: